Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced early Wednesday that Novartis (NYSE: NVS) has exercised its option to license valopicitabine. Valopicitabine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE